dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Changes in pharmacy retail market

Sotsiaalministeerium · 11. november 2019
Viit
5.2-7/2743-1
Registreeritud
11. november 2019
Dokumendi liik
Sissetulev kiri
Adressaat
PHOENIX Pharma SE
Saabumis/saatmisviis
e-post
Funktsioon
5.2 Tervishoiuteenuste kättesaadavuse korraldamine
Sari
5.2-7 Ravimite, meditsiiniseadmete ja verepreparaatidega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
5.2-7/2019
Vastutaja
Katri Eespere (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond)
Lahendamise tähtaeg
11. detsember 2019

Failid

  • 📎E-kiri.pdf85 KB
  • 📎PHOENIX Retail Nov2019.pdf114 KB

Sisu (failidest)

Saatja: HERFELD Stefan <[email protected]> Saadetud: 08.11.2019 15:30 Adressaat: <[email protected]>; <[email protected]>; <[email protected]>; Tanel Kiik <[email protected]>; SM Info <[email protected]> Koopia: JANKELEVITSH Leon <[email protected]> Teema: Changes in pharmacy retail market legislation entering into force on 1 April 2020 Dear Gentlemen, With this letter the PHOENIX group would like to address the serious concern related to major changes in Estonian law affecting whole pharmacy retail market and to protection of significant investments of Germany headquartered PHOENIX group in the Republic of Estonia. PHOENIX group is a leading pharmaceutical trader in Europe. In pharmaceutical wholesale PHOENIX group is active in 26 European countries supplying pharmacies and medical institutions with medicines and other health products. In pharmacy retail PHOENIX group operates more than 2,500 pharmacies in 14 countries most of them operate under the corporate brand BENU. We entered the Estonian market after acquisition of Finnish Tamro group in 2001. During the years of activity in Estonia, we have developed pharmaceutical wholesale activity and invested into and built up an operation of more than 80 BENU pharmacies. Today, PHOENIX group through BENU Apteek Eesti OÜ is one of the major service providers to the Estonian people. With the great concern, we have observed changes in Estonian legislation regarding pharmaceutical sector. In 2014 and 2015 amendments were adopted to the Estonian Medicinal Products Act stipulating that wholesalers of medicinal products are prohibited from having holdings in general pharmacies, or having any other dominant influence over holdings that have an activity licence of a general pharmacy. In addition, a requirement was established that a pharmacist must hold more than 50% of the shares of the pharmacy company. The above-mentioned amendments have a significant impact on the activities of the PHOENIX group in Estonia and endangers the availability of medicines in Estonia. As a consequence of the amendments to the Medicinal Products Act, PHOENIX group must divest its holdings in the pharmacies operating in Estonia by 1 April 2020 at the latest, or wind up their activities. Such regulation can be considered entailing expropriation of investments of foreign investors, incl. the PHOENIX group. Unfortunately, the amendments to the Medicinal Products Act do not prescribe any compensation for compulsory dissolution of the operation of general pharmacies belonging to wholesalers or financial support to pharmacists for buying the pharmacies for fair value. As far as the PHOENIX group is aware, no realistic steps have been taken to solve the specified problem by drafting an Act covering the compensation package to investors deriving from expropriation or supporting buyers/pharmacists. The fact that general pharmacies have to be shut down in the absence of pharmacists interested in the acquisition of a holding therein is an inevitable consequence of the regulation. Furthermore, it is extremely unlikely that the sufficient number of pharmacists will have the motive and financial capability to acquire the pharmacies from a current owner. Consequently, foreign investors are unable to get any fair compensation for their investments. Furthermore, no analysis has been made to specify how the availability of medicines is affected by the law amendments and guaranteed after 1 April 2020. We are seriously concerned that enforcement of the law amendments may lead to closing almost 300 pharmacies in Estonia as on 1 April 2020. I kindly ask the Social Affairs Committee of Estonian Parliament one more time to evaluate and recognise the risks that may occur to the patients and to availability of medicines that may become evident after 1 April 2020 when almost 300 pharmacies may be forced to end their activities. Additionally, consequences deriving from illegal expropriation must be considered as the investors shall have the right to file a compensation claim against the Estonian State. I truly believe that it is possible to find a solution best for patients and people of Estonia, but also for investors. Thank you very much for the consideration you will give to this letter and I remain at your disposal should you need any further information (contact person in Estonia: Mr Leon Jankelevitsh, Managing Director Tamro Baltics, e-mail [email protected], phone +37256 220 133). Best Regards, Stefan Herfeld Member of the Executive Board Retail PHOENIX Pharma SE Pfingstweidstraße 10-12 68199 Mannheim GermanyPhone +49 621 8505-251 PHOENIX Pharmahandel GmbH & Co KGPfingstweidstrasse 10 - 12D-68199 Mannheim Sitz der Hauptniederlassung: MannheimRegistergericht: Amtsgericht Mannheim HRA 3551 USt.-IdNr.: DE811737260 Glaeubiger-Identifikationsnummer: DE43ZZZ00000032466 Persoenlich haftende Gesellschafterin: PHOENIX Verwaltungs GmbHZweigniederlassung DeutschlandRegistergericht: Amtsgericht Mannheim HRB 718800 HauptniederlassungSitz Vaduz/LiechtensteinHandelsregister Liechtenstein Nr. FL-0002.468.204-0 Geschaeftsfuehrung: Sven Seidel (Vorsitzender), Helmut Fischer, Marcus Freitag, Frank Große-Natrop, Stefan Herfeld Diese E-Mail und alle Anhaenge enthalten vertrauliche und rechtlich geschuetzte Informationen, die ausschliesslich fuer den Gebrauch des Adressaten bestimmt sind. Das unerlaubte Kopieren, die unbefugte Weitergabe oder sonstiger ungenehmigter Gebrauch der E-Mail nebst den Anhaengen sind nicht gestattet. Sollten Sie nicht der richtige Adressat sein oder die E-Mail irrtuemlich erhalten haben, informieren Sie bitte den Absender unverzueglich telefonisch oder per E-Mail und vernichten diese E-Mail und alle Anhaenge sowie etwaige Kopien und Sicherungskopien. Vielen Dank. This e-mail message and all attachments transmitted with it may contain legally privileged and confidential information intended solely for the use of the addressee. If you are not the intended recipient or have received this e-mail in error, you are hereby notified that any dissemination, distribution, copying, or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately by telephone or by electronic mail, and delete this message and all copies and backups thereof. Thank you.
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel